CRISPR Therapeutics registers Phase 1/2 trial of CTX112 in neurologic autoimmune diseaseSep 4Trial updateCRISPR Therapeutics AGzugocabtagene geleucel
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial startsAug 3Quarterly updateCRISPR Therapeutics AGCTX340